**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Dimitrios Bampatsias, Columbia University Irving Medical Center, New York, NY, USA

**Main Body of the Abstract**
Background: Women with heart failure report worse symptom severity and depressed mood. Currently, there are no data about gender differences in patient reported outcomes in ATTR-CM.
Methods: This is a cross sectional study of patients with ATTR-CM presenting in Columbia University Medical Center from 2008 to 2023 and the Kansas City Cardiomyopathy Questionnaire (KCCQ) was recorded. Continuous data are presented as median and interquartile range (IQR).
Results:  Thirty-three females (19 wild type, 14 variant) and 253 males (208 wild type, 45 variant) were recruited (Table). The time of KCCQ completion from diagnosis was 14 (IQR: 3-36) months for males and 15 (IQR: 5 -27) for females (p=0.82). Overall, women had lower KCCQ score (70 vs 82, p=0.034). Women with wild type disease presented lower KCCQ (68 vs 83, p=0.017), but they were more often NYHA class III (58% vs 29%).  Also, women with V122I (N=8) variant presented lower KCCQ (61 vs 72), although not significant. In addition, women in NYHA III, presented significantly worse KCCQ, (52 vs 65, p=0.045). In univariable regression analysis, female gender was associated with lower KCCQ (mean difference: -8.4 points, p=0.03).  However, after adjustment for age, genotype, time from diagnosis and NYHA class, female gender was not associated with KCCQ score.
Conclusions: Female gender is not independently associated with worse patient reported health status in ATTR-CM.  However, women present with more advanced phenotype and thus worse reported outcomes, suggesting a delay in the diagnosis of ATTR-CM.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Dimitrios Bampatsias, Columbia University Irving Medical Center, New York, NY, USA

**Main Body of the Abstract**
**Background:** Women with heart failure report worse symptom severity and depressed mood. Currently, there are no data about gender differences in patient reported outcomes in ATTR-CM.
**Methods:** This is a cross sectional study of patients with ATTR-CM presenting in Columbia University Medical Center from 2008 to 2023 and the Kansas City Cardiomyopathy Questionnaire (KCCQ) was recorded. Continuous data are presented as median and interquartile range (IQR).
**Results:**  Thirty-three females (19 wild type, 14 variant) and 253 males (208 wild type, 45 variant) were recruited (Table). The time of KCCQ completion from diagnosis was 14 (IQR: 3-36) months for males and 15 (IQR: 5 -27) for females (p=0.82). Overall, women had lower KCCQ score (70 vs 82, p=0.034). Women with wild type disease presented lower KCCQ (68 vs 83, p=0.017), but they were more often NYHA class III (58% vs 29%).  Also, women with V122I (N=8) variant presented lower KCCQ (61 vs 72), although not significant. In addition, women in NYHA III, presented significantly worse KCCQ, (52 vs 65, p=0.045). In univariable regression analysis, female gender was associated with lower KCCQ (mean difference: -8.4 points, p=0.03).  However, after adjustment for age, genotype, time from diagnosis and NYHA class, female gender was not associated with KCCQ score.
**Conclusions:** Female gender is not independently associated with worse patient reported health status in ATTR-CM.  However, women present with more advanced phenotype and thus worse reported outcomes, suggesting a delay in the diagnosis of ATTR-CM.



Gender-related differences in patient reported outcomes in transthyretin amyloid cardiomyopathy: a cross-sectional study. PB97 (#460)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.